Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma Meeting Abstract
| Authors: | Ribas, A.; Butler, M.; Lutzky, J.; Lawrence, D. P.; Robert, C.; Miller, W.; Linette, G. P.; Ascierto, P. A.; Kuzel, T.; Algazi, A. P.; Postow, M. A.; Nathan, P. D.; Curti, B. D.; Robbins, P. B.; Li, X.; Blake-Haskins, J. A.; Gordon, M. S. |
| Abstract Title: | Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036900637 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2015.33.15_suppl.3003 |
| Notes: | Meeting Abstract: 3003 -- Source: Wos |
